Alnylam Pharmaceuticals Inc (ALNY)vsHalozyme Therapeutics Inc (HALO)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
HALO
Halozyme Therapeutics Inc
$63.24
+1.93%
HEALTHCARE · Cap: $7.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 166% more annual revenue ($3.71B vs $1.40B). HALO leads profitability with a 22.7% profit margin vs 8.5%. HALO trades at a lower P/E of 24.2x. HALO earns a higher WallStSmart Score of 70/100 (B).
ALNY
Hold49
out of 100
Grade: D+
HALO
Strong Buy70
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
+33.6%
Fair Value
$119.81
Current Price
$63.24
$56.57 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Strong operational efficiency at 56.3%
Revenue surging 51.6% year-over-year
Keeps 23 of every $100 in revenue as profit
Earnings expanding 36.2% YoY
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
ROE of 1.5% — below average capital efficiency
Trading at 154.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : HALO
The strongest argument for HALO centers on Operating Margin, Revenue Growth, Profit Margin. Profitability is solid with margins at 22.7% and operating margin at 56.3%. Revenue growth of 51.6% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : HALO
The primary concerns for HALO are Return on Equity, Price/Book.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while HALO is a growth play — different risk/reward profiles.
HALO carries more volatility with a beta of 1.02 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
HALO generates stronger free cash flow (218M), providing more financial flexibility.
Bottom Line
HALO scores higher overall (70/100 vs 49/100), backed by strong 22.7% margins and 51.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Halozyme Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?